Drug Boosts Survival for Women with Advanced Ovarian Cancer
Lynparza (Olaparib), a targeted cancer therapy, has recently shown a meaningful survival benefit after 5 years.
The Women’s Cancer Research Foundation (WCRF) annually publishes and funds numerous clinical studies on breast and gynecologic (ovarian, endometrial, and cervical) cancers. The WCRF’s oncology experts work tirelessly with the belief that each new clinical study has the potential to fundamentally improve the outcomes of patients diagnosed with breast and gynecologic cancers.